Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-cho, Tatsuno, Hyogo 679-5165, Japan.
National Institutes for Quantum and Radiological Science and Technology, QST Hospital, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
J Radiat Res. 2023 Jun 16;64(Supplement_1):i16-i24. doi: 10.1093/jrr/rrad012.
This study aimed to evaluate the efficacy and safety of particle therapy (proton beam therapy and carbon-ion radiotherapy) for esophageal cancer by analyzing prospective nationwide registry data from particle therapy facilities throughout Japan. Patients diagnosed with esophageal cancer who received particle therapy between May 2016 and June 2018 were recruited from the registries of 12 particle therapy centers in Japan. Eventually, we enrolled 174 patients who met the inclusion criteria. Of the 174 patients, 137 (78.7%) were male, with a median age of 69 years (range: 41-88 years). Clinical stages included I (n = 55; 31.6%), II (n = 31; 17.8%), III (n = 82; 47.1%), IV (n = 3; 1.7%) and unknown (n = 3; 1.7%) (Union for International Cancer Control, seventh edition), and the median follow-up period was 908 days (range: 76-1669 days) for all patients. The 3-year overall survival (OS) rate, the 3-year progression-free survival (PFS) rate and the 3-year local control (LC) rates were 60.5, 53.2 and 72.7%, respectively. For each clinical stage, the 3-year OS rates were I, 84.8%; II, 60.3% and III, 42.9%; the 3-year PFS rates were I, 71.9%; II, 58.3% and III, 37.0% and the 3-year LC were I, 78.4%; II, 79.8% and III, 65.2%, respectively. Notably, four patients (2.3%) with ≥Grade 3 cardiopulmonary toxicities were observed (Common Terminology Criteria for Adverse Events, version 5.0). Our study showed that particle therapy for esophageal cancer has lower rates of adverse cardiopulmonary events than X-ray radiotherapy.
本研究旨在通过分析日本各粒子治疗设施的前瞻性全国注册数据，评估粒子治疗（质子束治疗和碳离子放疗）在食管癌中的疗效和安全性。从日本 12 个粒子治疗中心的注册处招募了 2016 年 5 月至 2018 年 6 月期间接受粒子治疗的食管癌患者。最终，我们共纳入了 174 名符合纳入标准的患者。在这 174 名患者中，137 名（78.7%）为男性，中位年龄为 69 岁（范围：41-88 岁）。临床分期包括 I 期（n=55；31.6%）、II 期（n=31；17.8%）、III 期（n=82；47.1%）、IV 期（n=3；1.7%）和未知期（n=3；1.7%）（国际抗癌联盟第七版），所有患者的中位随访时间为 908 天（范围：76-1669 天）。3 年总生存率（OS）、3 年无进展生存率（PFS）和 3 年局部控制率（LC）分别为 60.5%、53.2%和 72.7%。对于每个临床分期，3 年 OS 率分别为 I 期，84.8%；II 期，60.3%和 III 期，42.9%；3 年 PFS 率分别为 I 期，71.9%；II 期，58.3%和 III 期，37.0%和 3 年 LC 分别为 I 期，78.4%；II 期，79.8%和 III 期，65.2%。值得注意的是，观察到 4 名（2.3%）患者发生≥3 级心肺毒性（不良事件常用术语标准，版本 5.0）。我们的研究表明，与 X 射线放疗相比，粒子治疗食管癌的不良反应心肺事件发生率较低。
